T1	Outcomes 20 39	efficacy and safety
T2	Outcomes 469 488	safety and efficacy
T3	Outcomes 1075 1167	CMV infection, CMV disease, rejection, opportunistic infections, and possible drug toxicity.
T4	Outcomes 1210 1242	6-month incidence of CMV disease
T5	Outcomes 1443 1467	incidence of CMV disease
T6	Outcomes 1675 1686	CMV disease
T7	Outcomes 1817 1843	incidence of CMV infection
T8	Outcomes 1931 1968	symptomatic herpes-simplex infections
